Wed, Mar 4, 2015, 3:35 PM EST - U.S. Markets close in 25 mins.

Recent

% | $
Quotes you view appear here for quick access.

Neptune Technologies & Bioressources, Inc. Message Board

halspeak 2 posts  |  Last Activity: Feb 27, 2015 2:49 AM Member since: Feb 6, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Earnings Call?

    by dontblamewelker Feb 26, 2015 10:48 AM
    halspeak halspeak Feb 27, 2015 2:49 AM Flag

    No guidance until they do a lot more work.. They will file the agreement next couple of days but legally, after that they have up to 70 days to file the details.. They feel it will be done sooner then that.. DR Systems, annual revenue was around $40m in 2013.. Audited numbers for 2014 was being worked on.. Merge is being conservative and is discounting 10-15% from 2013 numbers but feels with operating margins around 25%, it will still be accretive.. Financiers have up to 6 months to pull out (they were given puts at $ 4.11 if they don't like the audited numbers out of DR Systems since the deal was done before they saw all of it since DR Systems is also a competitor of Merge so they were reluctant to pass with all the information before the deal was signed..

    You should hear the CC at Merge website.. 38 minutes long..

  • Reply to

    Boom or bust?

    by batjuices Dec 20, 2014 1:00 AM
    halspeak halspeak Dec 26, 2014 3:08 PM Flag

    As for Spectral, one of the early stock market successes in Canada, its potential stems as much from years of capital market neglect as from the promise of its technology. Its stock price rose spectacularly in the early 1980s, almost reaching $1 billion in market value, on the strength of early excitement about its “point of care” cardiac diagnostic panel invention. Nothing of much value resulted from this early technology. A management change over ten years ago set the company on a new long and painfully dilutive path (again, based on the old model) to what may finally become a huge win for its long suffering shareholders. Ironically, its current technology marries a well-established Japanese filtering device to—you guessed it—a point-of-care diagnostic, albeit in the vastly more challenging area of septic shock. Sepsis remains one of health care’s most profound problems. If its current phase 3 Euprates trial on which management has “bet the company” succeeds in 2014, the share price win will be in multiples.

    Not sure if I can post the link but the above quote is from biotechnologyfocus-dot-ca by Tony Pullen in Part 2 of the article that covers Canadian Biotech companies..

NEPT
1.83-0.01(-0.54%)3:30 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.